Slide 1: Results Presentation for the Half-year ended 31 December 2024
For immediate release 11 February 2025 Results Presentation for the Half-year ended 31 December 2024 Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY) Please find attached the slides for the presentation on the half year results that will be given by the Chief Executive Officer and the Chief Financi
Slide 2: Driven by Our Promise: 2025 Half Year Results
Driven by Our Promise 2025 Half Year Results 11 February 2025
Slide 3: Important Notice and Disclaimer
Zahra K. IMPORTANT NOTICE AND DISCLAIMER This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to
Slide 4: Paul McKenzie, CEO & Managing Director
CEO Overview Financials Outlook CEO Overview Paul McKenzie CEO & Managing Director 3
Slide 5: Solid 1H25 Performance
CEO Overview Financials Outlook Solid 1H25 Performance1 CSL Behring Strong growth driven by Ig • Ig +15%, ALBUMIN® +9%, IDELVION® +6% Revenue +5% • • Gross margin +170 bps at CC Rika deployment well advanced NPATA2,3 +5% • iNomi implemented and delivering planned benefits • HEMGENIX® uptake accelera
Slide 6: CSL Behring Revenue $5,743m +10%
CEO Overview Financials Outlook Revenue $5,743m +10%1 Revenue ($m) Change1 Performance Major Brands • Strong performance across all geographies – PRIVIGEN® / INTRAGAM®+15%, HIZENTRA® +16% • Significant patient demand in all core indications Ig 3,174 +15% • HIZENTRA® ‒ Strong uptake of 50ml PFS ‒ Rem
Slide 7: Operational Highlights
CEO Overview Financials Outlook Operational Highlights • Underlying fundamentals of plasma collection remain strong: ‒ Plasma donations continuing to grow ‒ Further reduction in CPL ‒ Continued focus on driving centre efficiencies Rika Plasma Donation System • Horizon 1 delivering tangible yield ben
Slide 8: CSL Seqirus Revenue $1,661m (9%)
CEO Overview Financials Outlook Revenue $1,661m (9%)1 Therapy Revenue ($m) Change1 Performance Major Brands Egg Based 104 (16%) • Revenue impacted by: ‒ Decline in US vaccination rates Cell Culture 468 (12%) ‒ Shift in immunisation settings: medical vs pharmacy ‒ Competitive pressures Adjuvanted Egg
Slide 9: Operational Highlights
CEO Overview Financials Outlook Operational Highlights Seasonal Influenza Products Pandemic Influenza Product Innovation • FLUCELVAX® • Selected by BARDA, HERA and the UK • Phase III immuno-clinical study for Government for delivery of H5 vaccines aTIVc ‒ Positive CHMP opinion for 6- month+ age exte
Slide 10: CSL Vifor Revenue $1,079m +6%
CEO Overview Financials Outlook Revenue $1,079m +6%1 Therapy Revenue ($m) Change1 Performance Major Brands • EU FERINJECT® volume +6% Iron 527 +3% • US INJECTAFER® +3% • Launch of FERINJECT® in China and Canada on track a Nephrology: • MIRCERA® maintained market leadership in US c 387 (3%) b Dialysi
Slide 11: Operational Highlights
CEO Overview Financials Outlook Operational Highlights Commercial Execution Product Innovation • FERINJECT® • VELTASSA® ‒ Navigating competitive landscape ‒ Approved in Japan and further expanded market • CSL300 in ESKD ‒ EU volume growth +6% ‒ Global Phase III enrolment ‒ Significant unmet medical
Slide 12: Financials: John Levy, Interim CFO
CEO Overview Financials Outlook Financials John Levy Interim CFO 11
Slide 13: NPATA
CEO Overview Financials Outlook NPATA2,3 1H24 1H25 Change Rep @ CC %1 NPATA to CSL equity $2,109m $101m holders $2,017m $2,109m +5% FX $35m Acquired IP amortisation ($132m) ($155m) Other adjustments ($50m) $39m* Tax $32m $23m $2,074m NPATA $53m $76m $2,017m Attributable to NCI NPAT $1,920m $2,092m +
Slide 14: Financial Highlights
CEO Overview Financials Outlook CSL Group Financial Highlights 1H24 1H25 1H25 Change R&D 1 1 US$ Millions Rep Rep at CC % • Lower first half due to cessation of CSL112 Total Revenue 8,053 8,483 8,470 5% • FY25 guidance ~10% of revenue Gross Profit4 4,494 4,704 4,728 5% GP %4 55.8% 55.5% 55.8% G&A Sa
Slide 15: CSL Behring Segment Financial Highlights
CEO Overview Financials Outlook Segment Financial Highlights Path to Gross Margin Recovery Add Rika + INomi benefits CSL Behring • Optimise donor fees Change CPL Reduction • RIKA and I-Nomi 1 • Centre efficiencies US$ millions reported 1H24 1H25 % at CC Sales 5,093 5,611 10% • HEMGENIX® Other Revenu
Slide 16: CSL Seqirus and CSL Vifor Financial Highlights
CEO Overview Financials Outlook Segment Financial Highlights CSL Seqirus CSL Vifor Change Change 1 1 US$ millions reported 1H24 1H25 % at CC US$ millions reported 1H24 1H25 % at CC Sales 1,705 1,544 (10%) Sales 1,006 1,058 5% Other Revenue 99 117 16% Other Revenue 5 21 Total Revenue 1,804 1,661 (9%)
Slide 17: Outlook: Paul McKenzie, CEO & Managing Director
CEO Overview Financials Outlook Outlook Paul McKenzie CEO & Managing Director 16
Slide 18: FY25 Outlook
CEO Overview Financials Outlook FY25 Outlook CSL Behring CSL Seqirus • Underlying patient demand for • Higher H5 avian influenza Ig in core indications remains revenue in 2H strong • Preparation for • Momentum in HEMGENIX® FLUAD® launch in Germany uptake • Tullamarine facility • Preparing for launch
Slide 19: CSL Contacts
CSL Contacts Chris Cooper Investor Relations +61 455 022 740 chris.cooper@csl.com.au Bernard Ronchi Investor Relations +61 431 060 964 bernard.ronchi@csl.com.au Jimmy Baker Investor Relations +61 450 909 211 jimmy.baker@csl.com.au
Slide 20: Notes
Notes (#) Constant currency removes the impact of exchange Summary NPAT attributable to members Summary Revenue rate movements to facilitate comparability of operational of parent entity Reported revenue $8,483m performance for the Group. This is done in three parts: a) Reported net profit after tax
Slide 21: Appendix
Appendix 20
Slide 22: CSL Behring – Key Products
Appendix A CSL Behring – Key Products CSL Behring Therapy Group Sales $m Change1 % 1H25 Revenue By Therapy Group $m Privigen IVIG 2,024 15% Hizentra SCIG 1,100 16% IVIG $2,074 36% Albumin Albumin 672 9% SCIG $1,100 19% Idelvion Haemophilia 413 6% CSL Albumin $672 12% Behring Kcentra Specialty 293 (2
Slide 23: CSL Seqirus & CSL Vifor – Key Products
Appendix B CSL Seqirus & CSL Vifor – Key Products CSL Seqirus Therapy Group Sales $m Change1 % 1H25 Revenue By Therapy Group $m Fluad Adjuvanted 829 (17%) Flucelvax Cell culture 468 (12%) Cell Culture $468 28% Adjuvanted $829 50% Afluria Egg-based 104 (16%) Egg Based $104 6% CSL Pandemic Res Fees 89